The Xpert GI Panel identifies pathogens directly from stool specimens collected in Cary-Blair transport media.

New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global ...

Cepheid announced today that it has received FDA clearance for Xpert GI Panel, a multiplex PCR test designed to provide fast ...

These include fast, accurate, and easy to use tests for SARS-CoV-2, the virus causing COVID-19, Flu, MRSA, tuberculosis, and other HAI, sexual health, and oncology diseases. Each test is designed for ...

SUNNYVALE, Calif., Sept. 29, 2020 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert ® Xpress SARS-CoV-2 ...

SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification ...

SUNNYVALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new ...

(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...

(Reuters) - The U.S. Food and Drug Administration granted marketing approval to Cepheid's tuberculosis test that checks if the disease-causing bacteria carry antibiotic-resistant genetic markers. The ...